Deutsche Bank Reiterates “€65.00” Price Target for Fresenius SE & Co KGaA (FRE)

Deutsche Bank set a €65.00 ($75.58) target price on Fresenius SE & Co KGaA (FRA:FRE) in a research note issued to investors on Tuesday morning. The firm currently has a buy rating on the stock.

A number of other equities analysts also recently commented on FRE. UBS Group set a €46.00 ($53.49) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Monday. Credit Suisse Group set a €45.00 ($52.33) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Friday, December 14th. Cfra set a €45.00 ($52.33) target price on shares of Fresenius SE & Co KGaA and gave the stock a neutral rating in a research note on Friday, December 7th. DZ Bank reiterated a neutral rating on shares of Fresenius SE & Co KGaA in a research note on Thursday, October 18th. Finally, Sanford C. Bernstein set a €76.50 ($88.95) target price on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Friday, December 7th. Nine analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of €61.34 ($71.32).

Shares of FRE stock opened at €46.96 ($54.60) on Tuesday. Fresenius SE & Co KGaA has a 12 month low of €60.16 ($69.95) and a 12 month high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit